BMO Capital analyst Etzer Darout reiterated a Hold rating on Genmab (GMAB – Research Report) yesterday and set a price target of $46.00. The company’s shares closed yesterday at $27.59.
According to TipRanks, Darout is a top 100 analyst with an average return of 44.9% and a 56.13% success rate. Darout covers the Healthcare sector, focusing on stocks such as AstraZeneca, Exelixis, and ImmunoGen.
The word on The Street in general, suggests a Hold analyst consensus rating for Genmab with a $40.20 average price target, a 45.70% upside from current levels. In a report released on February 12, Leerink Partners also maintained a Hold rating on the stock with a $28.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $43.00 and a one-year low of $26.32. Currently, Genmab has an average volume of 620.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Genmab (GMAB) Company Description:
Genmab A/S is an international biotech company. It is specialized in creating and developing differentiated antibody therapeutics for the treatment of cancer. The company currently markets DARZALEX monoclonal antibody for the treatment of patients with multiple myeloma and Arzerra monoclonal antibody for the treatment of chronic lymphocytic leukemia.
Read More on GMAB:
